THE BOTTOM LINE
Tirzepatide has generally produced greater average weight reduction in obesity trials, but that does not make it the automatic choice. Semaglutide has a longer real-world history and its current labeling may fit some patients differently. The decision belongs with a licensed clinician and includes contraindications, side effects, coverage and continuity—not a single headline percentage.
SIDE-BY-SIDE
What actually differs
The status line
Semaglutide and tirzepatide are active ingredients used in FDA-approved prescription products. Brand and indication matter: a diabetes-labeled product is not interchangeable with an obesity-labeled product simply because the active ingredient is related or the injection looks similar.
Neither medication is an online commodity. Legitimate access begins with a licensed clinician evaluating eligibility, contraindications, current medications and monitoring needs.
What the efficacy numbers can—and cannot—tell you
Across pivotal obesity programs, both medications produced clinically meaningful average weight reduction when paired with reduced-calorie eating and increased physical activity. Tirzepatide generally produced larger average reductions, including in direct comparative research.
Trial averages are not personal forecasts. Enrollment criteria, dose, duration, adherence and discontinuation rules shape the result. A comparison page that quotes the highest number without matching the population and time period is marketing, not analysis.
Where the decision usually turns
The practical choice often turns on medical fit, side-effect tolerance, insurance rules, total cash price and whether the provider can manage dose escalation and problems between refills. Both labels carry important warnings and precautions, including boxed warnings concerning thyroid C-cell tumors observed in rodents; the relevance to humans is addressed in the prescribing information.
A strong telehealth program should disclose which product is being prescribed, whether it is FDA approved for the intended use, the complete recurring cost, who handles adverse effects and what happens if the medication becomes unavailable.
The Televetted decision rule
Do not choose from a before-and-after photo. First verify clinical eligibility and label-specific risks. Then compare the complete 12-month cost and care model. Only after those gates should average efficacy influence the choice.
PRIMARY & AUTHORITATIVE SOURCES
Check the underlying record
Regulatory status and labeling can change. Sources were reviewed on the article update date; current prescribing information controls.COMPARE THE CARE MODEL
Medication is only one part of the decision.
Use the 30-second filter to identify the costs, clinical safeguards and service terms worth checking before you enroll.
Find my starting point →